TBGNF News Alert Thromboogenics Nv (TBGNF) 9.6000 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Thromboogenics Nv (TBGNF) 9.6000 $TBGNF

ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
PR Newswire Europe - Thu Sep 05, 12:31AM CDT
LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion
PR Newswire - Fri Aug 16, 9:13AM CDT
Canada is first market outside the US and Europe where JETREA® is approved

Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire Europe - Fri Aug 02, 12:31AM CDT
LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire - Fri Aug 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire Europe - Wed Jun 12, 12:01AM CDT
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire - Wed Jun 12, 12:00AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA® (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA® as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present.

ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
PR Newswire Europe - Tue May 28, 11:03AM CDT
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ --

Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease
Business Wire - Tue May 28, 10:45AM CDT
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that they have entered into a research collaboration and license agreement with ThromboGenics NV to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a novel therapeutic of ThromboGenics' selection to have improved pharmaceutical characteristics and therapeutic benefits. The novel biologic will be designed to treat back of the eye diseases such as diabetic macular edema.

ThromboGenics' JETREA® Launched in Denmark and Sweden
PR Newswire - Mon May 27, 10:45AM CDT
Roll out in Finland and Norway to follow shortly

ThromboGenics Business Update
PR Newswire Europe - Thu May 16, 11:16AM CDT
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --

ThromboGenics' JETREA(R) Available in Germany Public and Private Market
PR Newswire Europe - Thu May 02, 12:31AM CDT
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Available in Germany Public and Private Market
PR Newswire - Thu May 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available.

Thrombocytopenia - Pipeline Review, H1 2013
M2 - Wed Apr 24, 5:49AM CDT
Research and Markets has announced the addition of the Thrombocytopenia - Pipeline Review, H1 2013 report to their offering. 'Thrombocytopenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis

ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK
PR Newswire - Thu Apr 11, 10:45AM CDT
First EU JETREA® order triggers EUR45 million milestone payment from Alcon to ThromboGenics

ThromboGenics Starts Trading as Part of the BEL20 Index Today
PR Newswire Europe - Mon Mar 18, 1:31AM CDT
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 86

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 69

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 207

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 255

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 0

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 41

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 63

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading

Top 5 Most Recently Viewed Articles

Lockheed Martin F-35 Production: Secretary's Inspiring Visit

Updated Category News Views 133

Secretary Visits Lockheed Martin's F-35 Production Facility Lockheed Martin (NYSE: LMT) proudly hosted the Secretary of War Pete Hegseth at its F-35 Lightning II production facility. This important visit highlighted the company's pivotal role in transforming defense acquisition processes. It also emphasized Lockheed Martin's dedication to delivering essential capabilities...

Continue Reading
OneAmerica Financial Foundation Empowers Caregiving Awareness

Updated Category News Views 220

OneAmerica Financial Foundation Supports Vital Caregiving Documentary The OneAmerica Financial Foundation has embarked on a significant journey by sponsoring an enlightening documentary titled "Caregiving." This compelling film delves into the experiences of caregivers, both professional and personal, across the United States. The documentary, narrated by Emmy...

Continue Reading
Multiconsult's Q2 2026: Profitability Rebounds

Updated Category News Views 26

Multiconsult's Financial Figures Take a Turn for the Better Times are looking up for Multiconsult ASA, a solid engineering firm based in Oslo. Their performance in the second quarter of 2026 spawned a tale of boosted revenues and healthier profitability. The crew isn't just resting on its laurels, as they're plugged into strategies that are set to carry them beyond 2026....

Continue Reading
KFC Revamps Menu with Original Honey BBQ and Classic Deals

Updated Category News Views 300

KFC's Exciting Revival: The Return of Iconic Flavors KFC has taken a bold step forward in its comeback era, reintroducing beloved menu items that fans have been eagerly awaiting. This time, the spotlight shines on the return of the highly sought-after Original Honey BBQ flavor. This mouthwatering sauce, which first won hearts in the late 1990s, will be back on October...

Continue Reading
Maxeon Solar Technologies Reports Financial Results for 2024

Updated Category News Views 262

Maxeon Solar Technologies Unveils Financial Outcomes for 2024 Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) has recently shared its financial results for the fourth quarter and entire fiscal year 2024, highlighting revenue reaching an impressive $509 million. The company faced significant challenges due to restrictions imposed by U.S. Customs and Border Protection (CBP)...

Continue Reading